Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update Pipeline expansion into neoantigens with multiple KRAS mutations as the first targets Acquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch protein Data from MDG1015 and multiple...

Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023 Planegg/Martinsried, August 10, 2023.  Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...